Search This Blog

Tuesday, June 25, 2019

Dermira up 9% premarket on Abbvie/Allergan deal

Dermira (NASDAQ:DERM) is up 9% premarket on light volume as buying ripples out from AbbVie’s bid for Allergan.
Its top drug is Obrexza (glycopyrronium) for primary axillary hyperhidrosis (excessive underarm sweating), approved in the U.S. a year ago.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)